News
-
-
-
COMMUNIQUÉ DE PRESSE
Formycon announces commercial launch of FYB201 (Ranibizumab) in Canada (RanoptoTM) and Switzerland (Ranivisio®)
Formycon announces commercial launch of FYB201 (Ranibizumab) in Canada and Switzerland, expanding availability in 17 countries. Biosimilar offers cost-effective treatment for retinal diseases -
-
-
COMMUNIQUÉ DE PRESSE
Formycon and Fresenius Kabi reach settlement agreement for ustekinumab biosimilar candidate FYB202 in Europe and Canada
Formycon and Fresenius Kabi reach settlement agreement with Johnson & Johnson for ustekinumab biosimilar FYB202 in Europe and Canada. Agreement terms kept confidential. Focus on expanding patient access and ensuring reliable treatment options -
-
-
-
COMMUNIQUÉ DE PRESSE
Gedeon Richter becomes strategic investor of Formycon via equity investment
Formycon AG announces strategic investment from Gedeon Richter, leading to a 9.08% equity takeover via cash capital increase of EUR 82.84 million. The investment will ensure high development pace and operational progress
